AS01 is efficient at promoting CD4 + T cell-mediated immune responses and is an appropriate candidate adjuvant for inclusion in vaccines targeting viruses or intracellular pathogens. Expert commentary: AS01 activity to enhance adaptive responses depends on synergistic activities of QS-21 and MPL.

2024年7月30日 · AS01是一种基于脂质体的疫苗佐剂系统，包含两种免疫刺激剂：3-O-去酰基-4'-单磷脂脂A和皂甙QS-21。 含有AS01的疫苗已经获得批准，并且已经在全球范围内数百万人中使用。 涉及领域：在这里，我们报告了对AS01作用机制的理解进展，这些进展有助于开发有效的疫苗，预防由疟疾、带状疱疹和呼吸道合胞病毒引起的疾病。 AS01诱导早期先天免疫激活，诱导具有优化的功能特性的T细胞介导和抗体介导的反应，并诱导免疫记忆。 含有AS01的疫苗似乎对 …

AS01 induces early innate immune activation that induces T cell-mediated and antibody-mediated responses with optimized functional characteristics and induction of immune memory. AS01-containing vaccines appear relatively impervious to baseline immune status translating into high efficacy across populations.

AS01 是由 MPL 和皂 QS-21 组成的复合佐剂,能够刺激基质细胞产生细胞因子,招募单核细胞和中性粒细胞，促进单核细胞分化成 树突状细胞，提高注射部位和引流淋巴结中树突状细胞的抗原递呈能力,辅助疫苗产生更高的适应性免疫反应。 AS01应用：疟疾疫苗Mosquirix佐剂及疱疹病毒疫苗Shingrix佐剂. AS01作用机制. AS02 水包油乳化剂. AS02是含有 MPL 和QS-21 的水包油乳化剂。 AS02应用：目前用于疟疾疫苗、结核病疫苗和艾滋病疫苗的研制。 AS03水包油佐剂. AS03 …

2024年4月17日 · Additionally, several other vaccines containing AS01 were approved; the RTS,S/AS01 E malaria vaccine (Mosquirix, GSK) for use in children, gE/AS01 B recombinant herpes zoster vaccine (RZV, Shingrix, GSK) for adults aged ≥50 years and immunocompromised persons aged ≥18 years, and most recently in a respiratory syncytial virus (RSV) vaccine ...

2016年8月2日 · AS01 is efficient at promoting CD4 + T cell-mediated immune responses and is an appropriate candidate adjuvant for inclusion in vaccines targeting viruses or intracellular pathogens. Expert commentary: AS01 activity to enhance adaptive responses depends on synergistic activities of QS-21 and MPL.

2017年1月1日 · AS01 emerged from GSK's Adjuvant Systems program initiated in the 1990s (see Fig. 14.1). 5 The program was spurred on by the licensing of the first vaccine produced by recombinant technology (the hepatitis B vaccine). Recombinant technology brought certain advantages to vaccine manufacture and opened the door to the rational design of antigens.

2022年6月25日 · AS01 B is a liposomal formulation of two immunostimulants namely 3-O-desacyl-4́-monophosphoryl lipid A (MPL) and QS-21. The liposomal formulation of AS01 B reduces the endotoxicity of MPL and the lytic activity of QS-21.

2022年3月26日 · GSK研发的重组带状疱疹疫苗Shingrix（CHO细胞）使用了AS01B作为佐剂，预防带状疱疹及带状疱疹后神经痛（PHN），临床数据显示保护效力超过90%。 图注：AS01佐剂的作用机制 来源：GSK Matrix-M佐剂由Quillaja皂苷制成，可增强Th1和Th2反应，增强免疫细胞运 …

2017年1月1日 · An excellent example of liposomal adjuvants is the clinically approved AS01b adjuvant developed by GSK. AS01b is licensed for use in the Herpes Zoster vaccine Shingrix as well as the malaria vaccine Mosquirix in the European Union, and has demonstrated excellent clinical efficacy [159,160].